urologytimes

urologytimes has been a member of Linktree for 9 months and joined in September 2025. The social media accounts linked to from urologytimes are: Facebook, Instagram, YouTube, X. Besides social media accounts, urologytimes has populated their site with The UroOnc Minute: Perioperative Treatment for High-Risk Localized Prostate Cancer, With Keyan Salari, MD, PhD | Urology Times, FDA updates in urology: June 2026 | Urology Times, FDA approves tebipenem pivoxil for complicated urinary tract infections | Urology Times, FDA approves generic Ga-68 PSMA-11 radiodiagnostic for prostate cancer | Urology Times, Urocross Expander demonstrates sustained LUTS improvement through 24 months in pivotal BPH trial | Urology Times, MPS2-AS outperforms mpMRI for prostate cancer upgrading during active surveillance | Urology Times, The UroOnc Minute: Pelvic Lymph Node Dissection During Radical Prostatectomy, with Giorgio Gandaglia, MD | Urology Times, FDA grants priority review to EV plus pembrolizumab for cisplatin-eligible MIBC | Urology Times, FDA grants Breakthrough Device Designation to urine-based multi-cancer early detection test | Urology Times, Metformin elevates anti-obesogenic metabolite Lac-Phe in prostate cancer | Urology Times, Trial launches of Edison Histotripsy System for benign prostatic hyperplasia | Urology Times, FDA approves accelerated thawing method for nadofaragene in NMIBC | Urology Times, IPSS advantage of 4.6 points favors Rezūm over alpha blocker plus 5-ARI | Urology Times, NCCN updates bladder cancer guidelines to include NAI plus BCG for papillary NMIBC | Urology Times, PRIMARY2: PSMA-PET/CT can safely reduce prostate biopsies in men with equivocal MRI | Urology Times, Lutetium-177 rosopatamab tetraxetan meets primary safety objectives in phase 3 trial for mCRPC | Urology Times, James R. Porter, MD, discusses Hugo RAS’s learning curve, modular design | Urology Times, FDA receives resubmitted sBLA for NAI plus BCG in papillary NMIBC | Urology Times, SUFU: Altaviva system provides sustained improvements in UUI symptoms and QOL | Urology Times, FDA approves Pylarify TruVu formulation of PSMA-PET agent piflufolastat F18 | Urology Times, FDA updates in urology: February 2026 | Urology Times, www.urologytimes.com, Final analysis confirms enzalutamide/radium-223 survival advantage in PEACE-3 | Urology Times, KEYNOTE-B15: EV/pembro sets new benchmark before cystectomy in MIBC | Urology Times, Expert discusses how CREST, POTOMAC highlight trade-offs in NMIBC treatment | Urology Times, FDA approves label changes for first batch of menopausal hormone therapy products | Urology Times, Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC | Urology Times, Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing | Urology Times, FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones | Urology Times, RCMIGI trial supports feasibility of reduced margins in image-guided prostate radiotherapy | Urology Times, Practical uses of AI across the urologic care continuum | Urology Times, Top 10 Urology Times prostate cancer articles of 2025 | Urology Times, FDA approves flibanserin for hypoactive sexual desire disorder in postmenopausal women | Urology Times, FDA grants 510(k) clearance to enhanced Revi System for urgency urinary incontinence | Urology Times, FDA approves rucaparib for chemotherapy-naïve, BRCA-mutated mCRPC | Urology Times, Experts urge FDA to revisit labeling for testosterone replacement therapy in men | Urology Times, FDA approves IsoPSA test as aid in the diagnosis of high-grade prostate cancer | Urology Times, FDA grants 510(k) clearance to new edition of Focal One robotic HIFU | Urology Times, FDA grants fast track designation to diagnostic agent for clear cell renal cell carcinoma | Urology Times, FDA approves fosfomycin for complicated urinary tract infections | Urology Times, PSMAddition: Adding 177Lu-PSMA-617 to ADT plus ARPI extends rPFS in mHSPC | Urology Times, Yair Lotan, MD, on navigating the next chapter in BCG-unresponsive NMIBC | Urology Times, CMS issues permanent J code for mitomycin for intravesical solution for LG-IR-NMIBC | Urology Times, EMBARK data indicate large OS benefit with enzalutamide/ADT in prostate cancer | Urology Times, KEYNOTE-905: EV/pembrolizumab emerges as new option for cisplatin-ineligible MIBC | Urology Times, ESMO 2025 recap: Top 13 trials in genitourinary oncology | Urology Times, Casdatifan shows safety, efficacy as monotherapy in late-line metastatic ccRCC | Urology Times, The Expert APProach: Training to Retain APPs in Urology, with J. Brandon Arruda, APRN, AGNP-C, CUNP | Urology Times, Glen Gejerman, MD, highlights phase 3 data on CAN-2409 in localized prostate cancer | Urology Times, ESMO 2025 preview: Key late-breaking abstracts in genitourinary oncology, Experts react to FDA approval of gemcitabine intravesical system in NMIBC, FDA greenlights phase 1 trial of alpha radioligand therapy in mCRPC, Medicare proposed rule for 2026: CMS, what are you doing to us?, FDA approves gemcitabine intravesical system for BCG-unresponsive NMIBC, YouTube, HHS requests testosterone therapy label updates, citing new safety data | Urology Times, HHS requests testosterone therapy label updates, citing new safety data | Urology Times, Kevin Zorn, MD, on selecting among different MIST options for BPH | Urology Times, How sexual interest shapes post-treatment bother in localized prostate cancer | Urology Times, Morcellator safety in HoLEP: Owning the checklist and recognizing early warning signs | Urology Times, FDA ODAC votes in favor of capivasertib plus abiraterone in PTEN-deficient mHSPC | Urology Times, Fractionated 225Ac–J591 shows early activity, preserved QOL in mCRPC | Urology Times, FDA signals potential pathway for testosterone therapy label expansion | Urology Times, BULLSEYE: 177Lu-PSMA-617 may delay disease progression in oligometastatic HSPC | Urology Times, Christopher Pieczonka, MD, on best practices with intravesical drug delivery systems | Urology Times, NCCN guidelines adopt IBCG risk model for intermediate-risk NMIBC | Urology Times, Nogapendekin alfa inbakicept receives EU authorization for BCG-unresponsive NMIBC | Urology Times, Urologist explains science behind HA penile injections | Urology Times, FDA approves sildenafil oral film for men with erectile dysfunction | Urology Times, FDA provides guidance on development pathway for testosterone therapy for women | Urology Times, Steven A. Kaplan, MD, discusses ProVee System and the future of BPH care | Urology Times, FDA approves ProVee System for benign prostatic hyperplasia | Urology Times, FDA grants 510(k) clearance to Vanquish Water Vapor System for intermediate-risk prostate cancer | Urology Times, Study validates diagnostic performance of CxBladder Triage Plus Test | Urology Times, The Expert Approach: Building the Future of Urology Teams, with Mark T. Edney, MD | Urology Times, CAN-2409 significantly improves disease-free survival in localized prostate cancer, Future of BPH management lies in precision, personalization, and technology, FDA approves pembrolizumab for subcutaneous injection for solid tumors, Facebook, Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC | Urology Times, Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC | Urology Times, Mark Garzotto, MD, discusses phase 3 data on aglatimagene in localized prostate cancer | Urology Times, Bladder Cancer Awareness Month: Emerging therapies and evolving standards of care | Urology Times, Sacituzumab govitecan/pembrolizumab achieves promising CR rate in MIBC | Urology Times, EAU 2026 Testicular Cancer Guideline reflects key updates in diagnosis and management | Urology Times, VIR-5500 enters expansion cohorts in phase 1 trial for metastatic prostate cancer | Urology Times, Stacy Loeb, MD, on emerging environmental data in prostate cancer | Urology Times, FDA grants clearance to Asurys Fluid Management System for endoscopic urologic procedures | Urology Times, Dietary changes and medications may help prevent recurrent nephrolithiasis | Urology Times, Hugo robot-assisted surgery system launches on US market | Urology Times, PSMA-PET/CT–guided salvage radiotherapy yields favorable outcomes after prostatectomy | Urology Times, Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer | Urology Times, Annual ACS NCDB report details national trends in prostate cancer care | Urology Times, The 2026 final rule: RVU adjustments, new codes among key changes | Urology Times, Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men | Urology Times, FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures | Urology Times, DISCUS trial shows improved PROs with de-escalation of chemotherapy in mUC | Urology Times, PAM50 biomarker is predictive of hormone therapy benefit in post-prostatectomy setting, FDA grants breakthrough device designation to Virtuoso Surgical Robotic System, FDA approves Altaviva device for urge urinary incontinence, AUA releases amendment to recurrent uncomplicated UTIs in women guideline, Instagram, FDA approves Titan Prime Inflatable Penile Prosthesis | Urology Times, X, FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC | Urology Times, FDA approves adjuvant belzutifan with pembrolizumab for ccRCC | Urology Times, The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD | Urology Times, FDA updates in urology: May 2026 | Urology Times, ASCO Annual Meeting | Conference | Urology Times, FDA approves durvalumab plus BCG for BCG-naïve, high-risk NMIBC | Urology Times, AUA | Conference | Urology Times, Morcellator safety in HoLEP: Owning the checklist and recognizing early warning signs | Urology Times, FDA updates in urology: April 2026 | Urology Times, FDA ODAC votes in favor of risk-benefit profile for capivasertib plus abiraterone in PTEN-deficient mHSPC | Urology Times, Cleveland Clinic | SAP Partner | Urology Times, The UroOnc Minute: KEYNOTE-B15 and Perioperative Therapy in MIBC, with Dr. Alfonso Gómez de Liaño Lista | Urology Times, LITESPARK-012 trial misses dual primary end points in advanced ccRCC | Urology Times, FDA grants priority review to EV plus pembrolizumab for cisplatin-eligible MIBC | Urology Times, FDA signals potential pathway for testosterone therapy label expansion | Urology Times, Meri-Margaret Deoudes on patient engagement in bladder cancer care | Urology Times, Akanksha Mehta, MD, on pre-operative counseling for vasectomy | Urology Times, EAU Annual Congress | Conference | Urology Times, The UroOnc Minute: LITESPARK-022 and Adjuvant Therapy in ccRCC, with Wesley Yip, MD | Urology Times, FDA updates in urology: March 2026 | Urology Times, Kidney Cancer | Clinical | Urology Times, Daniel George, MD, highlights survey of caregivers for patients with prostate cancer | Urology Times, EAU Annual Congress | Conference | Urology Times, ASCO GU recap: Sam Chang, MD, on KEYNOTE-B15, SWOG S1602 | Urology Times, FDA updates in urology: February 2026 | Urology Times, Stacy Loeb, MD, on microplastics and prostate cancer | Urology Times, GU Cancers Symposium | Conference | Urology Times, María Teresa Bourlon, MD, MS, FASCO, previews practice-changing research at ASCO GU 2026 | Urology Times, The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD | Urology Times, Society of Women in Urology (SWIU) | SAP Partner | Urology Times, Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing | Urology Times, The UroOnc Minute: En bloc resection vs TURBT, with Jeremy Y.C. Teoh, MBBS, FRCSEd, FCSHK, FHKAM | Urology Times, DSUI Urology on the Beach 2026, John Michael DiBianco, MD, highlights trial of stent omission after ureteroscopy | Urology Times, FDA updates in urology: December 2025 | Urology Times, Urology on the Beach 2026 brings new honors, debates, and innovation | Urology Times, Perioperative EV plus pembrolizumab extends survival in cisplatin-eligible MIBC | Urology Times, FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC | Urology Times, Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC | Urology Times, SUO Annual Meeting | Conference | Urology Times, FDA updates in urology: November 2025 | Urology Times, FDA approves pembrolizumab plus enfortumab vedotin for cisplatin-ineligible MIBC | Urology Times, Stacy Loeb, MD, discusses the evolving landscape of prostate cancer screening | Urology Times, FDA removes warning labels on hormone replacement therapy | Urology Times, LUGPA Annual Meeting | Conference | Urology Times, Ronney Abaza, MD, discusses the next wave of advancements in robotic surgery | Urology Times, FDA updates in urology: October 2025 | Urology Times, The Expert Approach: Building the Future of Urology Teams, with Mark T. Edney, MD | Urology Times, Scott Tagawa, MD, outlines key findings from the phase 3 PSMAddition trial | Urology Times, KEYNOTE-905: EV/pembrolizumab emerges as new option for cisplatin-ineligible MIBC | Urology Times, ESMO Annual Congress | Conference | Urology Times, First Assist: Navigating Geriatric Oncology in Urology, with Tullika Garg, MD, MPH, FACS | Urology Times, Glen Gejerman, MD, highlights phase 3 data on CAN-2409 in localized prostate cancer, Pearls & Perspectives: Bringing Clarity to Male Pelvic Pain, with Susan MacDonald, MD, The Expert APProach: Training to Retain APPs in Urology, with J. Brandon Arruda, APRN, AGNP-C, CUNP, FDA updates in urology: September 2025, What urologists can expect in Q4 of 2025, Mihir Shah, MD, on emerging neoadjuvant strategies in localized prostate cancer, ESMO 2025 preview: Key late-breaking abstracts in genitourinary oncology, Veda Giri, MD, on guidelines for germline testing in prostate cancer, First Assist: The Historical Context of NMIBC, with Kamal Pohar, MD, FDA approves Altaviva device for urge urinary incontinence, Pearls & Perspectives: Optimizing Outcomes in Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, Ashley Winter, MD, calls for label update on low-dose vaginal estrogen, Urology Times – News & Insights for Urologists & Health Professionals.